Biora Therapeutics, Inc. Net Income
Biora Therapeutics, Inc. reported Net Income of -$18.40 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2024-11-14
- Biora Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2024-09-30 was -$18.40M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2024-06-30 was $6.46M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2024-03-31 was -$4.19M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2023-12-31 was -$15.41M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$124.11M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$38.16M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$247.41M.
- Biora Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$192.53M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | -$18.40M 10-Q · filed 2024-11-14 | -$11.94M derived: sum of 2 quarters · filed 2024-11-14 | -$16.13M 10-Q · filed 2024-11-14 | -$31.54M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2024-06-30 | $6.46M 10-Q · filed 2024-11-14 | $2.28M 10-Q · filed 2024-08-12 | -$13.14M derived: sum of 3 quarters · filed 2024-11-14 | -$86.59M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2024-03-31 | -$4.19M 10-Q · filed 2024-11-14 | -$19.60M derived: sum of 2 quarters · filed 2024-11-14 | -$93.06M derived: sum of 3 quarters · filed 2024-11-14 | -$110.86M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-12-31 | -$15.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$88.87M derived: sum of 2 quarters · filed 2024-11-14 | -$106.67M derived: sum of 3 quarters · filed 2024-11-14 | -$124.11M 10-K · filed 2024-04-01 | |
| 2023-09-30 | -$73.45M 10-Q · filed 2024-11-14 | -$91.26M derived: sum of 2 quarters · filed 2024-11-14 | -$108.70M 10-Q · filed 2024-11-14 | -$122.42M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$17.81M 10-Q · filed 2024-11-14 | -$35.25M 10-Q · filed 2024-08-12 | -$48.97M derived: sum of 3 quarters · filed 2024-11-14 | -$54.08M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-03-31 | -$17.44M 10-Q · filed 2024-11-14 | -$31.16M derived: sum of 2 quarters · filed 2024-11-14 | -$36.28M derived: sum of 3 quarters · filed 2024-11-14 | -$41.79M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2022-12-31 | -$13.72M 10-K · filed 2023-03-30 | -$18.84M derived: sum of 2 quarters · filed 2023-11-13 | -$24.35M derived: sum of 3 quarters · filed 2023-11-13 | -$38.16M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$5.11M 10-Q · filed 2023-11-13 | -$10.63M derived: sum of 2 quarters · filed 2023-11-13 | -$24.43M 10-Q · filed 2023-11-13 | -$117.31M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$5.51M 10-Q · filed 2023-11-13 | -$19.32M 10-Q · filed 2023-08-14 | -$112.19M derived: sum of 3 quarters · filed 2023-11-13 | -$155.94M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-03-31 | -$13.81M 10-Q · filed 2023-11-13 | -$106.68M derived: sum of 2 quarters · filed 2023-11-13 | -$150.43M derived: sum of 3 quarters · filed 2023-11-13 | -$228.96M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2021-12-31 | -$92.87M 10-K · filed 2023-03-30 | -$136.62M derived: sum of 2 quarters · filed 2023-03-30 | -$215.15M derived: sum of 3 quarters · filed 2023-03-30 | -$247.41M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$43.74M 10-K · filed 2023-03-30 | -$122.28M derived: sum of 2 quarters · filed 2023-03-30 | -$154.54M 10-Q · filed 2022-11-14 | -$230.07M derived: sum of 4 quarters · filed 2023-03-30 | |
| 2021-06-30 | -$78.53M 10-K · filed 2023-03-30 | -$110.80M 10-Q · filed 2022-08-15 | -$186.32M derived: sum of 3 quarters · filed 2023-03-30 | -$233.39M derived: sum of 4 quarters · filed 2023-03-30 | |
| 2021-03-31 | -$32.26M 10-K · filed 2023-03-30 | -$32.26M 10-Q · filed 2021-05-13 | -$107.79M derived: sum of 2 quarters · filed 2023-03-30 | -$154.86M derived: sum of 3 quarters · filed 2023-03-30 | -$207.64M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | -$75.53M 10-K · filed 2022-03-28 | -$122.59M derived: sum of 2 quarters · filed 2022-03-28 | -$175.38M derived: sum of 3 quarters · filed 2022-03-28 | -$192.53M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$47.06M 10-K · filed 2022-03-28 | -$99.85M derived: sum of 2 quarters · filed 2022-03-28 | -$117.00M 10-Q · filed 2021-11-10 | -$167.48M derived: sum of 4 quarters · filed 2022-03-28 | |
| 2020-06-30 | -$52.78M 10-K · filed 2022-03-28 | -$69.94M 10-Q · filed 2021-08-12 | -$120.41M derived: sum of 3 quarters · filed 2022-03-28 | -$177.54M derived: sum of 4 quarters · filed 2022-03-28 | |
| 2020-03-31 | -$17.15M 10-K · filed 2022-03-28 | -$67.63M derived: sum of 2 quarters · filed 2022-03-28 | -$124.76M derived: sum of 3 quarters · filed 2022-03-28 | -$141.17M derived: sum of 4 quarters · filed 2022-03-28 | |
| 2019-12-31 | -$50.48M 10-K · filed 2021-03-18 | -$107.61M derived: sum of 2 quarters · filed 2021-03-18 | -$124.02M derived: sum of 3 quarters · filed 2021-03-18 | -$148.04M 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$57.13M 10-K · filed 2021-03-18 | -$73.54M derived: sum of 2 quarters · filed 2021-03-18 | -$97.56M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | -$16.41M 10-K · filed 2021-03-18 | -$40.43M 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | -$24.02M 10-K · filed 2021-03-18 |